Synapse - Michael Morris

Results (35)

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704)

Meeting Abstract

Zhang, T.; Ballman, K. V.; Choudhury, A. D.; Chen, R. C.; Watt, C.; Wen, Y.; Shergill, A.; Zemla, T. J.; Emamekhoo, H.; Vaishampayan, U. N.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Decision aids for localized prostate cancer: Initial outcomes from NCI Community Oncology Research Program Alliance Research Base Cancer Care Delivery Research (CCDR) Protocol-A191402CD: A cluster-randomized trial

Meeting Abstract

Tilburt, J. C.; Pacyna, J. E.; Petereit, D. G.; Kaur, J. S.; Rapkin, B. D.; Grubb, R.; Chang, G. J.; Morris, M. J.; Kovac, E.; Sloan, J. A.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA

Meeting Abstract

Morris, M. J.; De Wit, R.; Vogelzang, N. J.; Tagawa, S. T.; Higano, C. S.
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Evaluation of immune-related adverse events (irAE): Utilizing the patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) in a phase II study of ipilimumab (ipi) in men with castration-sensitive prostate cancer (CSPC)

Meeting Abstract

Vargas Pivato de Almeida, D.; Anderson, J.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Dayan, E. S.; Curley, T.; Arauz, G.; Baser, R. E.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

CDK12 alterations define a distinct molecular subtype of prostate cancers with unique genomic and clinical characteristics

Meeting Abstract

Nguyen, B.; Mota, J. M.; Nandakumar, S.; Stopsack, K. H.; Weg, E.; Rathkopf, D.; Morris, M. J.; Scher, H.; Kantoff, P. W.; Gopalan, A.; more...
Cancer Research (2020)

Fulltext@MSK | Save

Comparative survival of Asian and White metastatic castration-resistant prostate cancer men treated with docetaxel

Journal Article

Halabi, S.; Dutta, S.; Tangen, C. M.; Rosenthal, M.; Petrylak, D. P.; Thompson, I. M. Jr; Chi, K. N.; De Bono, J. S.; Araujo, J. C.; Logothetis, C.; more...
JNCI Cancer Spectrum (2020)

Fulltext@MSK | Save

A clinical evaluation of enzalutamide in metastatic castration-sensitive prostate cancer: Guiding principles for treatment selection and perspectives on research

Review

Laccetti, A. L.; Morris, M. J.; Kantoff, P. W.
OncoTargets and Therapy (2020)

Fulltext@MSK | Save

Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)

Journal Article

Chen, R. C.; Choueiri, T. K.; Feuilly, M.; Meng, J.; Lister, J.; Marteau, F.; Falchook, A. D.; Morris, M. J.; George, D. J.; Feldman, D. R.
Cancer (2020)

Fulltext@MSK | Save

Dickkopf-1 can lead to immune evasion in metastatic castration-resistant prostate cancer

Journal Article

Wise, D. R.; Schneider, J. A.; Armenia, J.; Febles, V. A.; McLaughlin, B.; Brennan, R.; Thoren, K. L.; Abida, W.; Sfanos, K. S.; De Marzo, A. M.; more...
JCO Precision Oncology (2020)

Fulltext@MSK | Save

Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer

Journal Article

Rao, A.; Scher, H. I.; De Porre, P.; Yu, M. K.; Londhe, A.; Qi, K.; Morris, M. J.; Ryan, C.
ESMO Open (2020)

Fulltext@MSK | Save